These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 11437681)

  • 1. Radioimmunotherapy: potential as a therapeutic strategy in non-Hodgkin's lymphoma.
    Wun T; Kwon DS; Tuscano JM
    BioDrugs; 2001; 15(3):151-62. PubMed ID: 11437681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response.
    Gisselbrecht C; Vose J; Nademanee A; Gianni AM; Nagler A
    Oncologist; 2009; 14 Suppl 2():41-51. PubMed ID: 19819923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy for B-cell non-hodgkin lymphomas.
    Tomblyn M
    Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.
    Visser OJ; Perk LR; Zijlstra JM; van Dongen GA; Huijgens PC; van de Loosdrecht AA
    BioDrugs; 2006; 20(4):201-7. PubMed ID: 16831019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
    DeNardo GL
    Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of Non-Hodgkin's lymphomas.
    Press OW; Leonard JP; Coiffier B; Levy R; Timmerman J
    Hematology Am Soc Hematol Educ Program; 2001; ():221-40. PubMed ID: 11722986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
    Schaefer-Cutillo J; Friedberg JW
    Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
    Shimoni A; Zwas ST
    Semin Nucl Med; 2016 Mar; 46(2):119-25. PubMed ID: 26897716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 131I-tositumomab.
    Lewington V
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concepts in radioimmunotherapy and immunotherapy: Radioimmunotherapy from a Lym-1 perspective.
    DeNardo GL
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S27-35. PubMed ID: 15786023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC; Cooney JP; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin).
    White CA
    J Exp Ther Oncol; 2004 Dec; 4(4):305-16. PubMed ID: 15844660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
    Macklis RM; Pohlman B
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.
    Chamarthy MR; Williams SC; Moadel RM
    Yale J Biol Med; 2011 Dec; 84(4):391-407. PubMed ID: 22180677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments for indolent lymphoma.
    Cheson BD; Gregory SA; Marcus R
    Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.